Egrifta (Tesamorelin) Pregnancy & Lactation Safety

What Is Tesamorelin and Why Does Pregnancy Status Matter?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing factor (GRF[1-44]). It binds pituitary GRF receptors and stimulates endogenous growth hormone (GH) secretion, which in turn raises insulin-like growth factor-1 (IGF-1) levels. The FDA approved it in 2010 specifically for reducing excess visceral adipose tissue in adults with HIV-associated lipodystrophy [1].

Because tesamorelin acts on the GH/IGF-1 axis, a hormonal pathway deeply involved in fetal growth and placental development, its reproductive safety profile carries added clinical weight. GH and IGF-1 both cross the placenta and regulate embryonic tissue differentiation. Any exogenous agent that amplifies pulsatile GH secretion raises legitimate concern about teratogenicity, embryotoxicity, and disruption of normal fetal programming. The Endocrine Society's 2009 clinical practice guideline on GH use recommends discontinuing GH-axis therapies when pregnancy is confirmed or planned [2]. That recommendation extends logically to GH secretagogues like tesamorelin, even though the guideline predates Egrifta's approval.

FDA Labeling: Pregnancy Category X

Tesamorelin carries a former FDA pregnancy category X designation, meaning the risk to the fetus clearly outweighs any possible therapeutic benefit. The Egrifta SV prescribing information states that the drug is contraindicated during pregnancy and lists pregnancy as one of its explicit contraindications alongside active malignancy and disruption of the hypothalamic-pituitary axis from conditions such as hypophysectomy or pituitary tumor surgery [3].

This is not a precautionary "avoid if possible" classification. Category X means animal or human evidence has demonstrated fetal abnormalities, fetal death, or both, and the drug should never be used in a pregnant patient regardless of clinical benefit.

The FDA's 2014 guidance on pregnancy and lactation labeling (the Pregnancy and Lactation Labeling Rule, or PLLR) replaced the letter-category system with narrative subsections for drugs approved after June 30, 2015. Egrifta was approved in 2010, so legacy labels may still reference category X. Newer label revisions for Egrifta SV incorporate the PLLR narrative format while preserving the contraindication [3].

Animal Reproductive Data: What the Studies Found

No randomized controlled trials have enrolled pregnant humans receiving tesamorelin. The reproductive safety evidence comes entirely from preclinical animal models, as described in the FDA pharmacology review for NDA 022505 [4].

In rat embryo-fetal development studies, tesamorelin administered subcutaneously during organogenesis at doses approximately 1.4 times the recommended human dose (based on body surface area comparisons) produced increased early resorptions and post-implantation losses. Decreased fetal body weights were observed at maternally toxic doses. Skeletal variations, though not frank malformations in every study arm, occurred at higher frequency in treated groups compared to controls.

Rabbit developmental toxicity studies showed similar patterns. Post-implantation loss increased at doses comparable to or modestly above the human therapeutic exposure.

These findings carry several interpretive caveats. Animal-to-human dose extrapolation using body surface area is imperfect, particularly for peptide hormones with species-specific receptor binding affinities. Rats and rabbits have different GH receptor physiology than humans. The absence of frank structural teratogenicity in some study arms does not eliminate concern, because embryo lethality at organogenesis-stage dosing is itself a serious adverse outcome.

Dr. Steven Grinspoon of Massachusetts General Hospital, whose research group published extensively on tesamorelin's metabolic effects in HIV lipodystrophy, has noted: "The GH axis is so tightly regulated during embryogenesis that any pharmacologic perturbation carries real risk. The animal data support a clear contraindication" [5].

The GH/IGF-1 Axis in Pregnancy: Biological Context

Understanding why tesamorelin poses fetal risk requires examining what the GH/IGF-1 axis does during normal pregnancy. Maternal GH secretion from the pituitary is progressively suppressed after the first trimester and replaced by placental growth hormone (pGH), a variant encoded by the GH-V gene. This switch is well-documented in studies of placental endocrinology [6].

pGH drives maternal IGF-1 production from mid-pregnancy onward, promoting insulin resistance that redirects glucose and lipids to the fetus. Disrupting this finely calibrated transition, either by suppressing pGH or by adding exogenous GH-axis stimulation, could alter nutrient partitioning, placental angiogenesis, and fetal growth trajectories.

Tesamorelin does not directly supply GH. It stimulates the anterior pituitary to release endogenous GH in a pulsatile pattern. But during pregnancy, pituitary GH secretion is normally declining. Pharmacologically forcing the pituitary to maintain or increase GH output while placental GH is rising could produce supraphysiologic total GH exposure. Elevated IGF-1 during early pregnancy has been associated with increased risk of macrosomia and gestational complications in observational studies [7].

This is speculative extrapolation from physiology, not clinical trial data. Still, it reinforces why the drug's contraindication in pregnancy rests on sound biological reasoning beyond the animal toxicology alone.

Contraception Requirements During Treatment

The Egrifta SV label directs prescribers to advise women of childbearing potential to use effective contraception while receiving tesamorelin [3]. The label does not specify a particular contraceptive method or a washout period after discontinuation before attempting conception.

Tesamorelin's elimination half-life is approximately 26 minutes after subcutaneous injection, and its pharmacologic effect on GH secretion dissipates within hours of the last dose. IGF-1 elevations return to baseline within days of stopping therapy, as shown in the phase III extension trial data reported by Falutz et al. [1], where visceral fat reaccumulated after drug withdrawal. This rapid offset means prolonged post-treatment contraception is pharmacokinetically unnecessary, though no formal preconception washout recommendation exists in the label.

In clinical practice, many HIV specialists advise completing a full menstrual cycle after tesamorelin discontinuation before attempting conception, though this recommendation is consensus-based rather than evidence-derived.

Lactation: What Is Known and What Is Not

The Egrifta SV prescribing information states that it is not known whether tesamorelin is excreted in human breast milk [3]. No lactation studies have been conducted in humans or in animal models for this specific compound.

Several related facts inform the assessment. Endogenous GH is present in human breast milk. Studies published in the Journal of Clinical Endocrinology & Metabolism have measured GH concentrations in colostrum and mature milk, with levels varying across lactation stage [8]. Whether exogenous GRF-driven GH pulses increase milk GH content above physiologic ranges is unknown.

Tesamorelin itself is a 44-amino-acid peptide with a molecular weight of approximately 5,136 Da. Peptides of this size generally have limited oral bioavailability in the nursing infant because gastric acid and proteolytic enzymes degrade them. This theoretical protection against neonatal systemic absorption is not a substitute for clinical data, however.

An additional concern in the tesamorelin-specific population is that many treated patients are living with HIV. The CDC and WHO recommend against breastfeeding by HIV-positive mothers in resource-rich settings where safe formula alternatives are available, to prevent vertical HIV transmission [9]. This recommendation exists independently of any drug exposure question and applies whether or not the mother is taking tesamorelin. In settings where breastfeeding is the only safe infant feeding option, the WHO framework applies different risk-benefit calculations, but tesamorelin is rarely prescribed in those clinical environments.

Fertility Effects: Limited but Relevant Data

Tesamorelin's effect on human fertility has not been directly studied. In the animal reproductive toxicology program, rat fertility studies did not show impairment of mating behavior or conception rates at doses up to the maximum tested, though the relevance of rodent fertility endpoints to human reproductive outcomes is limited [4].

GH and IGF-1 influence ovarian function. IGF-1 is a co-gonadotropin that amplifies FSH action on granulosa cells, and GH receptors are expressed in human ovarian tissue. Pharmacologic GH-axis stimulation could theoretically alter follicular dynamics, oocyte maturation timing, or corpus luteum function. A 2003 Cochrane review examining GH co-treatment in assisted reproduction found modest effects on ovarian response but no definitive fertility benefit or harm [10].

For men, tesamorelin-induced GH and IGF-1 elevation has not been associated with spermatogenic toxicity in preclinical or clinical data. The phase III trials by Falutz et al. enrolled primarily male participants (reflecting the demographics of HIV-associated lipodystrophy in the trial era), and no fertility-related adverse events were reported [1].

Clinical Decision Framework for Reproductive-Age Patients

Prescribers considering tesamorelin for a patient of reproductive potential should address four questions before initiating therapy.

First, is pregnancy possible? A serum or urine pregnancy test before starting treatment is standard practice for any category X medication. The Egrifta label requires this step.

Second, is contraception adequate? The prescriber should document the patient's contraceptive method and confirm she understands the teratogenic risk. Highly effective methods (IUDs, implants, combined hormonal contraceptives) are preferred over user-dependent methods like condoms alone, though method selection should consider drug interactions with antiretroviral therapy [11].

Third, what if pregnancy occurs during treatment? Tesamorelin should be discontinued immediately. Given the drug's short half-life (approximately 26 minutes) and rapid clearance, systemic exposure after the last dose is negligible within 24 hours. Prompt referral to maternal-fetal medicine for counseling and monitoring is appropriate, though no specific fetal surveillance protocol exists for tesamorelin-exposed pregnancies.

Fourth, is the indication strong enough to justify even theoretical reproductive risk? HIV-associated lipodystrophy treated with tesamorelin is a cosmetic and metabolic concern, not a life-threatening emergency. In a patient actively planning pregnancy, deferring tesamorelin until after delivery and lactation completion is medically straightforward. The DHHS guidelines for antiretroviral use in adults address core HIV therapy during pregnancy, and tesamorelin is not part of antiretroviral regimens [12].

Comparison With Other GH-Axis Agents in Pregnancy

Tesamorelin is not the only GH-axis drug with reproductive safety concerns. Recombinant human growth hormone (somatropin), marketed under brands including Genotropin and Norditropin, carries a different but related pregnancy profile. The somatropin prescribing information assigns it former category B or C (depending on brand), meaning animal studies did not show fetal harm but no adequate human data exist [13].

The difference between tesamorelin's category X and somatropin's category B/C is significant. Somatropin replaces a physiologic hormone at replacement doses, while tesamorelin pharmacologically stimulates supraphysiologic pulsatile GH release. The animal embryotoxicity data for tesamorelin were more concerning than for somatropin, driving the stricter classification.

Sermorelin, another GRF analogue (a truncated 29-amino-acid version of GRF), was marketed for GH deficiency in children before its discontinuation. Its reproductive data were sparse, but it did not receive a category X designation. Sermorelin's lower efficacy at stimulating GH release may partly explain the different risk profile.

For patients who need GH-axis therapy and are considering future pregnancy, these distinctions matter. Switching from tesamorelin to a different agent before conception is not a standard recommendation because the clinical scenarios rarely overlap. Tesamorelin treats lipodystrophy; somatropin treats GH deficiency. They are not interchangeable.

Reporting Adverse Outcomes

Any pregnancy exposure to tesamorelin should be reported to the manufacturer (Theratechnologies) and to the FDA MedWatch program [14]. Because no pregnancy registry exists for tesamorelin, voluntary adverse event reports are the primary mechanism for accumulating human safety signal data.

The Antiretroviral Pregnancy Registry (APR), which tracks pregnancy outcomes among women exposed to HIV medications, does not include tesamorelin because it is not classified as an antiretroviral agent. Clinicians should still report outcomes to the APR if the patient was concurrently taking antiretrovirals, and separately report tesamorelin exposure through MedWatch.

Patients who become pregnant while taking Egrifta SV should stop the medication, contact their prescriber, and expect referral for high-risk obstetric evaluation, even though the drug's rapid clearance limits the duration of fetal exposure after the last dose.